Search Results (1,265)

Objectives: The aim of this study is to evaluate the safety and efficacy of repeat transcatheter aortic valve implantation (redo-TAVI) in the polish population. Methods: In this multicentre nationwide registry (ClinicalTrials.gov identifier, NCT03361046), we provide characteristics, periprocedural variables and long-term outcomes of high-risk patients who underwent redo-TAVI. Results: The mean age among 32 individuals who underwent redo-TAVI was 75 ± 13 years, and 62.5% were male. The mean time from index TAVI to redo-TAVI was 4.7 ± 3.5 years, with failed procedures (up to 1 year) occurring in 7 (21.9%) and failed transcatheter heart valve (THV, beyond 1 year) in the remaining majority of the 25 (78.1%) patients. Computed tomography-based native bicuspid aortic anatomy was found frequently in 37.5% of cases (58.3% in failed procedures and 41.7% in failed THV). The mean failed THV size was large (27.7 ± 3 mm) and predominantly presenting with pure regurgitation (59.4%). In more than two-thirds (68.7%), balloon-expandable or self-expandable THV was the most common strategy of redo-TAVI. None or mild regurgitation was found in 90.6%, and the mean transvalvular gradient was 13.1 ± 5.5 mmHg, with only three cases with >20 mmHg of the residual gradient (9.4%). Peri-procedural and 30-day complications were low, and cardiovascular and all-cause mortality at 1 year was 9.4 and 15.6%, respectively. There was a relatively high incidence of non-procedural stroke after redo-TAVI (n = 5, 15.6%), with all cases observed after 30 days. Conclusions: Initial data of redo-TAVI in Poland suggest that the procedure is safe and characterized by favourable efficacy and low rates of short-term adverse outcomes. A high frequency of baseline native bicuspid anatomy and late stroke occurrence after the redo-procedure warrants further investigation in larger cohorts. Full article

The intensification of agricultural practices and the consequent dramatic decrease in soil organic matter has increased the use of organic fertilizer to recover soil fertility and plant productivity. The aim of this study was to compare the effect of three amendments obtained from the recycling of urban and agri-food wastes on rhizosphere microbial community, soil, and plant nutrient status. The experiment was carried out on rhizobox-grown, 1-year-old vines of Sangiovese (Vitis vinifera L.), grafted onto 110 Richter (V. berlandieri × V. rupestris) planted in April 2023. Twenty-four rhizoboxes were filled with soil collected from a field trial in which three types of amendments had been applied since 2019. In detail, the complete randomized experimental design (with four replications) compared the following treatments: (1) municipal organic waste compost (ACM), (2) agri-food organic waste compost (ACF), (3) defecation gypsum (GDD), and (4) a control that received 60 kg of N ha⁻¹ year⁻¹ (CK). The application of the amendments increased the soil concentration of total C, total N, and pH. The application of ACM increases soil K and Zn and the concentration of N and K in plant roots. The application of all the amendments increased leaf N concentration in comparison with CK, but only ACF increased leaf P. ACM was the most effective in promoting microbial biodiversity, increasing phyla like Bacillota, Pseudomonata, and Bacteroidota, including genra like Bacillus, Neobacillus, Paenibacillus, and Pseudomonas. ACF promoted Nitrosospherota and Chitinophaga, and GDD promoted Chloroflexota and Agrobacterium. Full article

Poly (ADP-ribose) polymerase 1 (PARP1) is an important enzyme that plays a central role in the DNA damage response, facilitating repair of single-stranded DNA breaks via the base excision repair (BER) pathway and thus genomic integrity. Its therapeutic relevance is compounded in breast cancer, particularly in BRCA1 or BRCA2 mutant cancers, where compromised homologous recombination repair (HRR) leaves a synthetic lethal dependency on PARP1-mediated repair. This review comprehensively discusses the recent advances in computational chemistry for the discovery of PARP1 inhibitors, focusing on their application in breast cancer therapy. Techniques such as molecular docking, molecular dynamics (MD) simulations, quantitative structure–activity relationship (QSAR) modeling, density functional theory (DFT), time-dependent DFT (TD-DFT), and machine learning (ML)-aided virtual screening have revolutionized the discovery of inhibitors. Some of the most prominent examples are Olaparib (IC₅₀ = 5 nM), Rucaparib (IC₅₀ = 7 nM), and Talazoparib (IC₅₀ = 1 nM), which were optimized with docking scores between −9.0 to −9.3 kcal/mol and validated by in vitro and in vivo assays, achieving 60–80% inhibition of tumor growth in BRCA-mutated models and achieving up to 21-month improvement in progression-free survival in clinical trials of BRCA-mutated breast and ovarian cancer patients. These strategies enable site-specific hopping into the PARP1 nicotinamide-binding pocket to enhance inhibitor affinity and specificity and reduce off-target activity. Employing computation and experimental verification in a hybrid strategy have brought next-generation inhibitors to the clinic with accelerated development, higher efficacy, and personalized treatment for breast cancer patients. Future approaches, including AI-aided generative models and multi-omics integration, have the promise to further refine inhibitor design, paving the way for precision oncology. Full article

Background and Objective: Zanubrutinib, a next-generation Bruton’s tyrosine kinase inhibitor (BTKi), has demonstrated promising efficacy in chronic lymphocytic leukemia (CLL), including treatment-naïve (TN) and relapsed/refractory (R/R) patients. However, evidence synthesis across clinical trials remains limited. We conducted a systematic review and single-arm meta-analysis to evaluate the efficacy of zanubrutinib in CLL. Methods: This study was performed in accordance with PRISMA guidelines and Cochrane recommendations. PubMed, Medline, Scopus, and Web of Science were searched up to August 2025 using terms related to zanubrutinib and CLL/SLL. Eligible studies included clinical trials of zanubrutinib in TN or R/R CLL/SLL patients. Risk of bias was assessed using the JBI tool for non-randomized studies and for RCTs. Pooled estimates of efficacy outcomes were calculated using a random-effects model. Pooled estimates were calculated using the DerSimonian–Laird random-effects model, which accounts for both within- and between-study variability. Results: Seven studies (n > 1000) were included, enrolling both TN and R/R patients across diverse global populations. The pooled overall response rate (ORR) was 93.3% (95% CI, 86.7–99.8%) in mixed TN and R/R populations, 94.4% (95% CI, 91.6–97.3%) in TN patients, and 83.9% (95% CI, 75.0–92.8%) in R/R patients. Complete response (CR) rates were 12.2% (95% CI, 0.3–24.2%) overall, 13.8% (95% CI, 1.5–26.2%) in TN patients, and 5.0% (95% CI, 0.3–9.8%) in R/R patients. Partial response (PR) rates reached 86.0% (95% CI, 82.6–89.5%) in TN and 63.2% (95% CI, 53.5–73.0%) in R/R patients. Progressive disease was rare (≤1% in R/R cohorts). Heterogeneity was moderate to high across several outcomes. Conclusions: Zanubrutinib demonstrates favorable efficacy in CLL, achieving high ORR in both TN and R/R patients, with particularly durable responses in TN populations. Although complete response rates remain modest, especially among R/R patients, overall disease control appears consistent. These findings support zanubrutinib as an effective treatment option across CLL settings; however, variability among studies and the modest CR rates highlight the need for longer follow-up and direct comparative trials to further define its clinical role. Full article

Background: Heart failure (HF) with pulmonary hypertension due to left-sided heart disease (PH-LHD) is associated with poor prognosis. Dapagliflozin showed benefits in terms of ejection fraction (EF); meanwhile, sildenafil improved pulmonary pressures and right ventricular function in PH -LHD in recent clinical studies. This study assesses the potential additive effects of dapagliflozin and sildenafil on cardiac function and pulmonary hemodynamics in this population. Methods: In this prospective, randomized, controlled trial, 93 participating patients with HF and PH-LHD were randomly assigned to receive dapagliflozin (control group, n = 48) or dapagliflozin plus sildenafil 25 mg/day (test group, n = 45) in addition to conventional therapy for HF for 12 weeks. The primary outcomes were assessing changes in echocardiographic hemodynamic parameters. Secondary outcomes included outcomes, changes in cardiac enzyme (troponin), kidney function (serum creatinine), and lipid profile. Results: The average baseline median left ventricular ejection fraction (LVEF) for both groups was 30%, and the Pulmonary Artery Systolic Pressure (PASP) median was 50 mmHg. At follow-up, PASP had declined, and EF had improved compared to baseline. However, there were no statistically noticeable variations between the groups (p = 0.458, 0.331, respectively). No notable changes were observed in secondary and safety outcomes, including hospitalization rate, number of deaths, kidney function, and cardiac enzymes (p = 0.524, 1, 0.923, and 0.574, respectively). Conclusions: Addition of sildenafil to dapagliflozin did not demonstrate any significant clinical or hemodynamic benefit over dapagliflozin monotherapy in HF patients and PH-LHD. Further studies are warranted to evaluate the effects over the long term. Full article

Marine magnetic surveys are vast and time-consuming, and researchers have long been seeking an economical mode for large-area data acquisition. A towed magnetic measurement system was developed based on the motion characteristics of the wave glider. By modifying the SeaSPY2 magnetometer, a twin-body towed configuration was developed, in which an S-shaped towing cable mitigates motion-induced impacts from the platform, and a high-precision GNSS positioning module was integrated into the system. Sea trials were conducted in the coastal waters near Qingdao. The results indicated that the system achieved an average cruising speed of 0.56 m/s, with the towed body’s pitch and roll angles controlled within ±5° and ±1°, respectively. The dynamic noise was measured at 0.0639 nT (Level 1), and the internal consistency for repeated survey lines and cross lines was 1.832 nT and 1.956 nT, respectively, meeting the requirements of marine magnetic survey standards. The system offers unmanned operation, zero carbon emissions, and a minimal environmental footprint, and long endurance, supporting applications such as nearshore exploration, mapping in sensitive marine areas, and underwater magnetic target detection. The research provides a novel unmanned technological solution for deep-sea magnetic surveys and lays the foundation for low-cost, cluster-based operations. Full article

Background: Diabetic foot ulcers (DFUs) carry high risks of infection, amputation, and mortality. We systematically reviewed randomized controlled trials (RCTs) of negative-pressure wound therapy (NPWT), including single-use systems, for clinically uninfected DFUs (with sensitivity analyses for mixed/infected cohorts). Methods: We searched PubMed and Scopus (1 January 2004–30 June 2024). Dual reviewers performed screening and extraction; risk of bias was assessed with Cochrane Risk of Bias 2 (RoB 2) and certainty of evidence with GRADE. When ≥2 trials reported comparable outcomes, we used random-effects meta-analysis. The DiaFu cohort reported in two publications was counted once across analyses. Results: Eleven RCT publications (n = 1699; 10 unique cohorts) met criteria; eight trials (n = 1456) informed the primary endpoint. Trials largely excluded severe ischemia; findings therefore apply mainly to neuropathic or mixed-etiology DFUs with adequate perfusion. NPWT increased complete healing at 12–16 weeks (risk ratio [RR] 1.46, 95% CI 1.21–1.76; I² = 48%) and shortened time to healing (mean difference –18 days, 95% CI −28 to −8). Effects were similar for conventional and single-use NPWT. Outcomes did not vary systematically within commonly used pressure ranges (approximately −80 to −125 mmHg). Only two RCTs reported direct cost data (exploratory). Moderate heterogeneity (Higgins’ I² 48–68%) reflected variation in ulcer severity, device type/settings, dressing-change frequency, and off-loading protocols. Conclusions: NPWT probably improves short-term healing of clinically uninfected DFUs compared with standard care and may reduce minor amputations, without increasing adverse events. Certainty is moderate for healing and low for most secondary outcomes. Benefits appear consistent across device classes and may support earlier discharge and community-based care. Evidence gaps include ischemia-dominated ulcers, long-term outcomes (recurrence and limb preservation), adherence mechanisms, and contemporary cost-effectiveness. Full article

Background/Objectives: Activities of daily living (ADL) are critical for independence after stroke, yet many survivors remain functionally limited. Vibration therapy (VT), including whole-body and focal modalities, has been proposed as an adjunct to enhance recovery, but effects on ADL remain unclear. This study aimed to evaluate the overall effectiveness of VT on ADL and to identify moderating factors. Methods: A systematic review and meta-analysis were conducted following PRISMA 2020 guidelines. Thirteen controlled trials (12 RCTs, 1 nRCT) involving VT in stroke were included. Standardized mean differences (Hedges’ g) were synthesized using random-effects models. Meta-regression and subgroup analyses examined moderators such as session number, vibration parameters, stroke stage, and ADL subdomains. Risk of bias was assessed with RoB 2 and ROBINS-I. Results: VT produced a small but significant effect on ADL (Hedges’ g = 0.19; 95% CI: 0.06–0.33; p = 0.008), though significance was lost after adjustment for publication bias. Heterogeneity was moderate (I² = 34%). Session number was the only significant moderator (p = 0.045), explaining ~24% of variance, with the greatest benefit in the 13–24 session range (g = 0.34; 95% CI: 0.05–0.63). Subgroup analysis showed improvement in physical function/mobility (g = 0.32; p = 0.048), but not in self-care or quality-of-life outcomes. Other parameters were not significant moderators. Conclusions: VT confers modest benefits for ADL after stroke, particularly in mobility-related domains. Session number appears clinically important, with 13–24 sessions suggesting an optimal dose window. Full article

Background/Objectives: Zinc deficiency remains a public health concern in South Asia but is rarely studied through gestation to infancy. Methods: We identified maternal and infant factors related to plasma zinc of 3 mo old Bangladeshi infants (n = 317) in the context of a trial of a daily antenatal to 3 mo postpartum multiple micronutrient supplementation (MMS) with 15 vitamins and minerals, including 12 mg zinc, versus iron–folic acid (IFA). Factors explored included maternal age, parity, and plasma zinc in early (pre-supplementation) and late pregnancy, at 3 months postpartum, and in milk; cord blood zinc (n = 83); birth outcomes; and infant feeding and biomarkers. Consequently, infant zinc was explored with 3 mo anthropometry and growth rates. Results: Mean ± SD infant plasma zinc was 15.63 ± 6.65 µmol/L, with 10.1% deficiency (<9.9 µmol/L). In adjusted analyses, infant zinc was positively associated with maternal age [20–30 years +0.11 µmol/L (p = 0.018) and ≥30 years +0.28 µmol/L (p = 0.003) relative to <20 years], maternal early pregnancy zinc (+0.01 µmol/L per 1 µmol/L maternal zinc, p = 0.011), and infant ferritin (+0.001 µmol/L per 1 µg/L, p = 0.007); conversely, infant zinc was −0.13 µmol/L lower (p = 0.013) with maternal parity ≥2 versus 0–1 and with partial versus exclusive breastfeeding (−0.15 µmol/L, p = 0.038). Relationships with MMS, maternal later pregnancy, postpartum, milk, and cord blood zinc were absent. Length-for-age (+0.02 per µmol/L, p = 0.047) but not weight-for-length Z-scores at 3 months were associated with infant zinc. Conclusions: Thus, infant zinc was associated with pre- but not post-MMS maternal zinc, age and parity, feeding style, and infant iron status. Infant length but not weight was associated with plasma zinc. Full article

Objectives: This study assessed the influence of oral and topical sodium bicarbonate (SB) on recovery and soccer-specific performance after exercise-induced muscle damage (EIMD). Methods: In a randomized, double-blind, placebo-controlled, parallel group design, 24 soccer players were allocated to oral SB, topical SB (PR Lotion, Momentous), or placebo (PLA) (n = 8 per condition) and attended six laboratory sessions: (i) familiarization, (ii) baseline measures, and (iii) four experimental trials on consecutive days. Muscle damage was induced on day 1 using 40 × 15 m sprints, after which either 0.3 g·kg⁻¹ body mass (BM) SB (SB-ORAL), 0.9036 g·kg⁻¹ BM PR Lotion (SB-LOTION), or an equivalent PLA was given. Recovery outcomes were measured post-EIMD, 1 d, 2 d, and 3 d post (day 1–4). Soccer-specific performance was repeated 3 d post, with supplements administered again 2 h pre-exercise. Recovery measures included muscle soreness, vertical jump height, and maximal voluntary isometric contraction. Illinois agility test (IAT), 8 × 25 m repeated sprints, and Yo-Yo Intermittent Recovery Test Level 2 (Yo-Yo IR2) were assessed as soccer-specific performance. Results: Neither SB-ORAL nor SB-LOTION accelerated indices of recovery but decline in soccer-specific performance from baseline to 3 d post was attenuated for SB-ORAL, with significant effects for IAT (p = 0.032, g = 1.69) and Yo-Yo IR2 (p = 0.026, g = 1.61) compared with PLA. Conclusions: SB did not accelerate recovery following EIMD but prescribing oral SB before subsequent exercise might rescue key performance indicators. These findings offer implications for practitioners working with soccer players during periods where full recovery is not achieved. Full article

Background: The problem of antibiotic resistance is becoming increasingly serious worldwide due to uncontrolled prescription of antibiotics. Studies show conflicting results on the use or not of antibiotic prophylaxis associated with dental implant placement; its benefits are unclear, and its use is increasingly questioned. The aim of this randomized controlled clinical trial (RCT) was to compare early implant failure and postoperative infectious complications between two groups of healthy, non-penicillin-allergic patients who received a single prophylactic dose of 2 g amoxicillin versus placebo 1 h before surgery for implants placed in a single operative field. Methods: A double-blind, parallel-group, single-center RCT was conducted. One hundred patients met the inclusion criteria and were randomly assigned to the amoxicillin (n = 50) or placebo (n = 50) group. The primary endpoints analyzed were early implant failure and the presence of postoperative infection at 7, 14, 30 and 90 days. The recommendations of the CONSORT 2025 statement for RCT reporting were followed. Results: A total of 151 implants were placed in 96 patients and 12 implants failed; 6 implants in the antibiotic group (7.7%) and 6 implants in the placebo group (8.2%), so no statistically significant differences were observed between groups in the rate of early implant failure. In contrast, 11 implants developed postoperative infection; 2 in the antibiotic group (2.6%) and 9 in the placebo group (12.3%), reaching statistically significant differences (p = 0.028). Conclusions: The use of antibiotic prophylaxis in healthy patients is not necessary to prevent early failure of implants placed in a single operative field; however, the higher rate of infectious complications in patients without antibiotic therapy still raises a question that requires further investigation. Full article

Lycium ruthenicum leaves (LRL), as an agricultural by-product rich in bioactive compounds, can be used as an unconventional feedstuff in animal diets and have the potential to improve animal health. This study investigates the effects of dietary supplementation with graded levels of LRL on rumen fermentation, meat amino acid and fatty acid profiles, and rumen bacterial diversity in sheep. Forty three-month-old male Dorper × Hu crossbred F1 lambs with an initial body weight of 29.58 ± 2.06 kg were randomly assigned to four groups (n = 10). Over a continuous 63-day trial period, the lambs were fed diets containing 0%, 5%, 10%, and 15% LRL, respectively. At the end of the trial, rumen fluid and longissimus dorsi muscle samples were collected to assess rumen fermentation characteristics, bacterial community structure, and meat quality. The results showed that: (1) The concentrations of acetate, butyrate, and total volatile fatty acids (TVFA) in the rumen were increased in the LRL5% group (p < 0.05 or p < 0.01). (2) The relative abundance of the phylum Firmicutes and the genus Ruminococcus increased (p < 0.05), while the relative abundance of the genus Prevotella decreased (p < 0.05) in the LRL5% group. (3) Meat L* increased (p < 0.05), and a* decreased (p < 0.05) in the LRL-supplemented groups. (4) The content of sweet amino acids in meat increased in LRL groups (p < 0.05). Moreover, the contents of non-essential amino acids, sweet amino acids, and total amino acids in meat increased linearly with increasing dietary LRL levels (p < 0.05). (5) Compared with the CON group, the content of C18:0 in meat decreased in the LRL5% group (p < 0.05), while the content of C20:1 increased in the LRL10% group (p < 0.05). In conclusion, dietary supplementation with LRL can improve meat quality, rumen fermentation, and rumen bacterial community structure in sheep. The recommended dietary inclusion level of LRL ranges from 5% to 15%. Full article

Background: Autism Spectrum Disorder (ASD) affects ~1 in 36 children and is increasingly studied as a candidate for non-invasive neuromodulation. Two of the most widely applied modalities are quantitative EEG (QEEG)-guided repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS), both targeting the dorsolateral prefrontal cortex (DLPFC). While both have shown promise, questions remain regarding their relative clinical profiles and scalability. Objective: To conduct a within-cohort reanalysis of QEEG-guided rTMS outcomes in paediatric ASD and to contextualise these findings alongside published reports of home-supervised tDCS. Methods: Individual participant data (n = 56, ages 6–17) from a prospective rTMS cohort were reanalysed, focusing on the Social Responsiveness Scale (SRS-2), Autism Diagnostic Observation Schedule (ADOS-2), Aberrant Behavior Checklist (ABC), Repetitive Behavior Scale–Revised (RBS-R), and QEEG biomarkers. Findings were then situated within a narrative synthesis of published paediatric tDCS trials, which consistently report caregiver-supervised feasibility but did not provide raw, baseline-adjusted data suitable for reanalysis. Results: rTMS was associated with large within-cohort improvements (Hedges’ g ≈ 1.0–1.6), including an 11-point reduction in SRS-2 T-scores, a 12-point reduction in ABC totals, and robust QEEG normalisation (β/γ suppression, α enhancement). Published tDCS studies report moderate, clinically meaningful improvements in social communication, executive functioning, and regulation (Cohen’s d ≈ 0.4–0.6), with excellent adherence and no serious adverse events. Conclusions: rTMS produced robust behavioural and neurophysiological improvements within its cohort, while published tDCS trials demonstrate moderate, feasible benefits in home settings. Because of incomplete baseline data and protocol differences, no direct statistical comparison was possible. These findings suggest complementary roles: rTMS as a high-intensity clinic-based intervention, and tDCS as a scalable, family-centred option. A stepped-care framework that combines both modalities should be considered hypothesis-generating only and requires validation in harmonised, randomised controlled trials. Full article

Background/Objectives: Osteopenia is common in postmenopausal women and predisposes to osteoporosis and fracture, representing a population at risk of bone loss but without indication for pharmacologic therapy. Conventional calcium salts offer modest, often transient gains in bone mineral density (BMD). We evaluated whether CalGo^®, a salmon bone complex containing microcrystalline hydroxyapatite within a collagen-rich matrix, preserves BMD versus placebo in post-menopausal women with osteopenia. Methods: In a 24-month, randomized, double-blind, placebo-controlled trial, 80 women (50–80 years) with dual-energy X-ray absorptiometry (DXA)-confirmed femoral-neck osteopenia were assigned to CalGo^® (2 g/day) or placebo. The prespecified primary endpoint was 24-month change in femoral-neck BMD (g/cm²) analyzed by linear regression (unadjusted and baseline-adjusted). Secondary endpoints included lumbar spine and distal radius BMD, serum P1NP and β-CTX-I, health-related quality of life, and safety. Results: The primary analysis included participants with 24-month DXA (CalGo^® n = 29; placebo n = 30). Femoral-neck BMD was maintained with CalGo^® (+0.003 g/cm²; +0.4%) but declined with placebo (−0.017 g/cm²; −2.4%), yielding a significant baseline-adjusted between-group difference of +0.019 g/cm² (95% confidence interval (CI) 0.001–0.038; p = 0.044). Lumbar-spine loss was attenuated with CalGo^® (−0.005 g/cm²; −0.3%) versus placebo (−0.028 g/cm²; −3.4%); the adjusted difference favored CalGo^® (+0.026 g/cm²; p = 0.058). In exploratory responder analysis, ≥1% lumbar-spine gain was more likely with CalGo^® (32.5% vs. 11.4%; OR 3.61; p = 0.043). No treatment effects were observed at the distal radius, in P1NP or β-CTX-I, or in EQ-5D-3L/EQ-VAS. CalGo^® was well tolerated with no hepatic or renal safety signals. Conclusions: CalGo^® maintained femoral-neck bone mineral density and reduced lumbar-spine loss over 24 months in osteopenic women, with good tolerability. These findings support its potential role as a nutritional approach for maintaining bone health. Full article

Background: The majority of injuries among older adults occur due to unexpected and sudden incidents in the home environment. This study aimed to develop a protocol for the design of the health belief model-based program for preventing unintentional home injuries in older adults and to evaluate the effectiveness of the program. Methods: The study proposed in this protocol, Safety and Home Injury Prevention for Seniors (SHIPs), is a single-blind, parallel-group, randomized controlled trial. A total of 54 Korean older adults (≥65 years) will be randomly assigned to either (1) the intervention group (n = 27), which will receive the SHIPs program, or (2) the control group (n = 27), which will attend four lecture-only sessions. The efficacy of the program will be assessed via tests performed at baseline, 1 week after program completion, and 1 month after program completion, and analyses of the changes in injury occurrences, risk factors, preventive behaviors, beliefs about safety and injury prevention, psychological health, physiological function, and health-related quality of life. Expected Results: The SHIPs intervention is expected to reduce home injuries and enhance awareness and preventive behaviors among community-dwelling older adults. It may also improve their physical and psychological health and overall quality of life. Conclusions: The SHIPs intervention may serve as an effective community-based strategy to promote injury prevention and improve the overall well-being of older adults. Full article